Donald Trump again claims he lowered Medicare insulin prices to $35 — ‘not Lyin’ Kamala’

Doubling down on misleading claims repeated throughout the campaign, Donald Trump again insisted in a social media outburst that he was responsible for lowering the monthly out-of-pocket price cap on insulin for Medicare recipients to $35, a statement which Vice President Kamala Harris’s campaign and a leading health policy organization have disputed.

“I was the one who got the $35 Insulin, not Lyin’ Kamala,” Trump said in a Truth Social post Tuesday night that diverted into rants on a hodgepodge of topics. “I’ve never seen a group that lies so much, like making up, out of thin air, that the U.S. produced 818,000 New Jobs, when it was a total fraud that they had to recant; or that she worked so hard at McDonalds, BUT SHE NEVER WORKED THERE. They even said that they knew nothing about Deranged Jack Smith going after their political opponent, ME - And that was the biggest lie of them all. But fear not, we will WIN and, MAKE AMERICA GREAT AGAIN!”

Trump’s claims that his administration lowered insulin for Medicare enrollees “is a blatant lie,” according to a fact check from the Harris campaign’s rapid response team after Trump’s vice presidential running mate repeated the same line at a rally in September.

ALSO READ: Busted: Bundy collaborator fueled FEMA conspiracy in Hurricane Helene aftermath

“[Trump got] insulin down to $35 a vial. Thank Donald Trump for that,” Sen. J.D. Vance (R-OH) said. “Don’t let Kamala Harris lie and take credit for it.”

“Trump did not cap insulin costs, Biden-Harris did for seniors through the Inflation Reduction Act," Harris’ campaign wrote in a social media post. "Trump’s Project 2025 wants to repeal it, which would raise insulin costs for over a million Americans."

KFF, a health information nonprofit, released a report earlier this year detailing “the facts about the $35 insulin copay cap in Medicare.”

It concludes that Trump has inaccurately stated that President Joe Biden had “nothing to do with” lowering insulin copayments and compares the Trump administration’s “voluntary, time-limited model” – which reduced costs for about 800,000 insulin users – to the Biden administration’s model which was available to an estimated 3.3 million people in 2020.